Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $39.3 million.

  • Altimmune's Cash from Financing Activities rose 1469285.71% to $39.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.8 million, marking a year-over-year increase of 8675.75%. This contributed to the annual value of $10.0 million for FY2024, which is 8833.52% down from last year.
  • Latest data reveals that Altimmune reported Cash from Financing Activities of $39.3 million as of Q3 2025, which was up 1469285.71% from $52.2 million recorded in Q2 2025.
  • Over the past 5 years, Altimmune's Cash from Financing Activities peaked at $72.8 million during Q4 2023, and registered a low of -$302000.0 during Q1 2023.
  • Over the past 5 years, Altimmune's median Cash from Financing Activities value was $12.5 million (recorded in 2021), while the average stood at $18.1 million.
  • The largest annual percentage gain for Altimmune's Cash from Financing Activities in the last 5 years was 16929534.88% (2023), contrasted with its biggest fall of 10949.39% (2023).
  • Quarter analysis of 5 years shows Altimmune's Cash from Financing Activities stood at $12.5 million in 2021, then plummeted by 100.34% to -$43000.0 in 2022, then soared by 169295.35% to $72.8 million in 2023, then plummeted by 86.14% to $10.1 million in 2024, then skyrocketed by 290.17% to $39.3 million in 2025.
  • Its last three reported values are $39.3 million in Q3 2025, $52.2 million for Q2 2025, and $34.1 million during Q1 2025.